Core Viewpoint - Concrete Pumping Holdings, Inc. reported a decline in revenue and net income for both the fourth quarter and the full fiscal year 2025, primarily due to a slowdown in residential and commercial construction demand amid high interest rates and macroeconomic challenges [5][10][12]. Financial Results Summary - **Fourth Quarter Fiscal Year 2025**: - Revenue was $108.8 million, down from $111.5 million in the same quarter of fiscal year 2024, a decrease of 2.4% [5][6]. - Gross profit decreased to $43.3 million from $46.2 million, with a gross margin decline to 39.8% from 41.5% [6][7]. - Net income was $5.3 million, down from $9.4 million, resulting in diluted earnings per share of $0.09 compared to $0.16 [8][12]. - Adjusted EBITDA was $30.7 million, down from $33.7 million, with an adjusted EBITDA margin of 28.2% compared to 30.2% [9]. - **Fiscal Year 2025**: - Total revenue was $392.9 million, a decrease from $425.9 million in fiscal year 2024, representing a decline of 7.7% [10][12]. - Gross profit for the year was $151.1 million, down from $165.8 million, with a gross margin of 38.5% compared to 38.9% [10][11]. - Net income for the year was $6.4 million, down from $16.2 million, with diluted earnings per share of $0.09 compared to $0.26 [12]. - Adjusted EBITDA for the year was $97.0 million, down from $112.1 million, with an adjusted EBITDA margin of 24.7% compared to 26.3% [12]. Segment Performance - **U.S. Concrete Pumping**: - Fourth quarter revenue was $72.2 million, down from $74.5 million, with net income decreasing to $1.1 million from $3.8 million [14]. - Fiscal year revenue was $260.5 million, down from $291.0 million, resulting in a net loss of $1.9 million compared to a net income of $6.5 million [15]. - **U.S. Concrete Waste Management Services**: - Fourth quarter revenue increased by 8% to $21.3 million, with net income of $3.0 million compared to $3.9 million in the prior year [16]. - Fiscal year revenue increased by 6% to $75.4 million, with net income rising to $5.9 million from $5.5 million [18]. - **U.K. Operations**: - Fourth quarter revenue was $15.3 million, down from $17.1 million, with net income decreasing to $1.2 million from $1.7 million [19]. - Fiscal year revenue was $57.0 million, down from $64.0 million, with net income of $2.4 million compared to $4.2 million [20]. Management Commentary - The CEO highlighted the company's resilience and adaptability in a challenging macroeconomic environment, emphasizing the importance of cost management and operational flexibility [4]. The company aims to generate strong free cash flow and is considering selective share repurchases or targeted acquisitions for future growth [4]. Liquidity and Capital Expenditures - As of October 31, 2025, the company had $425.0 million in debt, with net debt of $380.6 million and total available liquidity of $359.5 million [13]. - The company plans to accelerate approximately $22.0 million in capital equipment investments into fiscal year 2026 due to upcoming stricter emissions laws [22][23]. Fiscal Year 2026 Outlook - The company expects fiscal year 2026 revenue to range between $390.0 million to $410.0 million, with adjusted EBITDA projected between $90.0 million to $100.0 million, and free cash flow to be at least $40.0 million [21].

Core Insights - Brookdale Senior Living Inc. (BKD) reported a weighted average occupancy of 82.4% for December 2025, reflecting a 310 basis points increase year-over-year but a slight decline of 10 basis points from November 2025 [1] Group 1: Occupancy and Capacity - In Q4 2025, BKD's weighted average occupancy reached 82.5%, up from 79.4% a year ago and 81.8% in Q3 2025, indicating consistent growth throughout 2025 [2] - The company has the capacity to serve approximately 51,000 residents across 41 states [2] - BKD has improved its occupancy significantly from a pandemic low of 69.4% in March 2021, aiming to enhance operational efficiency and profitability [5] Group 2: Financial Performance - Resident fee revenues increased by 4.5% year-over-year in the first nine months of 2025, with expectations for continued growth [3] - For 2025, BKD forecasts a 5.25-6% increase in average monthly senior housing resident fee revenue per available unit (RevPAR) and adjusted EBITDA in the range of $455 million to $460 million [3][10] Group 3: Earnings Estimates - The Zacks Consensus Estimate for BKD's Q4 2025 earnings is a loss of 16 cents per share, reflecting a 5.8% year-over-year improvement, although the company has struggled to meet earnings estimates consistently [4] - BKD has met earnings estimates only once in the past four quarters, with an average surprise of 37.1% [4]

2 ICR Conference Presentation BUILDING A SCALABLE, MULTI-BRAND SUPERFOOD PLATFORM January 13, 2026 Important Disclosures Cautionary "Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on Laird Superfood, Inc.'s (the "Company", "Laird Superfood", "Laird" or "LSF") current expectations or forecasts of future events and are not guarantees of future performance. Forward-lo ...

Core Insights - Neogen Corporation (NEOG) reported adjusted earnings per share (EPS) of 10 cents for Q2 fiscal 2026, exceeding the Zacks Consensus Estimate by 42.86%, but down from 11 cents in the same quarter last year [2] - Revenues for the quarter decreased by 2.8% year-over-year to $224.69 million, with core revenues increasing by 2.9%, surpassing the Zacks Consensus Estimate by 7.93% [3][10] Revenue Breakdown - The Food Safety segment generated revenues of $165.6 million, reflecting a 0.8% year-over-year increase, driven by 4.1% core revenue growth, despite a negative impact from divestitures and discontinued products [4] - The Animal Safety segment reported revenues of $59.1 million, down 11.8% year-over-year, with a slight core revenue increase of 0.1% and a significant negative impact from divestitures [5] Margin and Expense Analysis - Gross profit for Q2 declined by 5.9% year-over-year to $106.7 million, with a gross margin contraction of 153 basis points to 47.5% [6] - Sales and marketing expenses decreased by 9.1% to $42.3 million, while administrative expenses rose by 12.9% to $65 million, leading to an operating loss of $5.4 million compared to a profit of $3.9 million in the prior year [7] Cash Position and Liabilities - Neogen's cash and cash equivalents at the end of Q2 totaled $145.3 million, an increase from $138.9 million at the end of Q1 [8] - The company has total outstanding debt of $800 million and a committed borrowing capacity of $201.5 million [8] Fiscal 2026 Outlook - Neogen raised its fiscal 2026 revenue guidance to a range of $845 million to $855 million, up from the previous estimate of $820 million to $840 million, with adjusted EBITDA expected to be around $175 million [10][11] - The company noted encouraging early progress with a return to positive core growth across the enterprise [12] Segment Performance Highlights - Within the Food Safety segment, the strongest core revenue growth was observed in Indicator Testing and Culture Media, attributed to higher sales of sample collection products [13] - The Biosecurity product category in Animal Safety saw strong growth in insect control product sales [13]

Core Insights - Alignment Healthcare, Inc. reported a health plan membership of approximately 275,300 as of January 1, 2026, reflecting a 31% year-over-year growth following a strong annual enrollment period [1] - The company anticipates health plan membership to reach between 290,000 and 296,000 by year-end 2026, indicating a growth of approximately 24% to 27% compared to the midpoint of its year-end 2025 membership guidance [2] - The expected consensus adjusted EBITDA for 2026 is approximately $145 million, which is within the full-year guidance range [2][8] - The company reaffirmed its full-year 2025 guidance on health plan membership, revenue, adjusted gross profit, and adjusted EBITDA [3][8] Company Performance - Since its IPO in 2021, Alignment Healthcare has achieved a compounded annual membership growth rate of approximately 30%, demonstrating sustained performance in the Medicare Advantage market [1] - 100% of its members are enrolled in plans rated 4 stars or higher for the second consecutive year, according to Centers for Medicare & Medicaid Services star ratings [4] Business Model and Strategy - The company emphasizes a care-centered model that aims to deliver high-quality outcomes and create shareholder value by serving seniors [4] - Alignment Healthcare's mission is to provide high-quality, low-cost care for its Medicare Advantage members, supported by a customized care model and a 24/7 concierge care team [7]

Core Viewpoint - The Oncology Institute, Inc. (TOI) reaffirms its 2025 guidance and provides a preliminary outlook for 2026, expecting significant revenue growth and the potential for Adjusted EBITDA profitability for the first time as a public company [1][2][3]. 2026 Outlook - TOI anticipates total revenue for 2026 to be between $630 million and $650 million, indicating a 28% growth from the midpoint of 2025 guidance [2]. - Approximately $150 million of the expected revenue will come from Capitation revenue, driven by the expansion of delegated contracts in Florida and strong performance in the Dispensary segment [2]. - Profitability from newly onboarded delegated contracts is expected to build progressively throughout 2026, with more substantial economic benefits anticipated in 2027 [2]. Adjusted EBITDA Expectations - Adjusted EBITDA for 2026 is projected to be in the range of $0 million to $9 million, marking TOI's first full year of Adjusted EBITDA profitability as a public entity at the midpoint of this range [3]. Longer-Term Outlook - The company aims for total revenue growth at an annual rate of approximately 20% through 2028, with Capitation and Dispensary revenue expected to rise to about 30% and 50% of total revenue, respectively [5]. - As TOI scales, margins are projected to expand to the mid-single-digit range as a percentage of revenue by 2028, supported by the asset-light delegated capitated model and continued SG&A leverage [6]. Company Overview - Founded in 2007, TOI is a leading provider of value-based oncology care in the United States, serving approximately 1.9 million patients through over 100 clinics and affiliate locations across five states [7].

Core Viewpoint - Olin Corporation has revised its fourth quarter 2025 adjusted EBITDA outlook to approximately $67 million, significantly lower than the previous estimate of $110 to $130 million, primarily due to issues in the Chlor Alkali Products and Vinyls business [1][2]. Company Overview - Olin Corporation is a leading vertically integrated global manufacturer and distributor of chemical products, including chlorine, caustic soda, vinyls, and various other chemicals, as well as a major U.S. manufacturer of ammunition [3]. Financial Performance - The adjusted EBITDA for the fourth quarter 2025 is now expected to be around $67 million, a decrease from the earlier forecast of $110 to $130 million [1]. - The earnings shortfall is attributed to an extended planned maintenance turnaround and unplanned downtime at the Freeport, Texas operations, along with lower-than-expected pipeline chlorine demand [1][2]. Operational Challenges - The Chlor Alkali Products and Vinyls segment faced a significant decline in chlorine demand and operational issues at the Freeport site, which included a planned turnaround and interruptions in raw material supply from a third party [2]. - The Freeport site has since returned to normal operations, but the impact of these challenges has affected the overall financial outlook [2].

RESPONSIBLE CARE® OUR COMMITMENT TO SUSTAINABILITY Refer to the Appendix for additional notices of caution regarding forward looking information. 2 TSX: CHE.UN 2026 Guidance 2026 Guidance: 2026 GUIDANCE Chemtrade Logistics Income Fund (TSX: CHE.UN) January 8, 2026 CAUTION REGARDING FORWARD- LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking statements within the meaning of certain securities laws, including the Securities Act (Ontario). Forward-looking statements ...

Core Insights - Collegium Pharmaceutical, Inc. has announced its financial guidance for 2026, projecting product revenues between $805 million and $825 million, with Jornay PM net revenue expected to be between $190 million and $200 million, and adjusted EBITDA anticipated in the range of $455 million to $475 million [1][4][5] Financial Performance - The company reported record growth in 2025, driven by strong performance in Jornay PM and sustained revenue growth across its pain management portfolio [2][5] - The financial guidance for 2025 was raised to a net revenue range of $775 million to $785 million and adjusted EBITDA between $460 million and $470 million, with results expected to be reported in February 2026 [5] Business Development - Collegium has successfully closed a $980 million syndicated credit facility, which will be used to repay a previous term loan and provide capital for future business development opportunities [5] - The company has entered into agreements with Hikma Pharmaceuticals for the authorized generic versions of Nucynta and Nucynta ER, with expected launches in 2026 [5] Strategic Focus - Collegium aims to balance capital deployment by paying down debt, repurchasing shares, and exploring opportunities to expand and diversify its portfolio [2][5] - The company is committed to improving the lives of patients with serious medical conditions through its diversified biopharmaceutical portfolio [5][6]

Core Viewpoint - Simply Good Foods Company reported modestly better-than-expected financial performance for the first quarter of fiscal year 2026, reaffirming its full-year outlook and emphasizing its leadership in the nutritional snacking category, particularly with brands Quest and OWYN [2][3]. Financial Performance - Net sales for the first quarter were $340.2 million, a decrease of 0.3% compared to the same period last year, with Quest growing by 9.6% while Atkins and OWYN saw declines of 16.5% and 3.3% respectively [3][8]. - Gross profit was $109.9 million, down 15.8% year-over-year, with a gross margin of 32.3%, reflecting a 590 basis point decline due to elevated input costs [5][8]. - Operating expenses decreased by 4.7% to $72.3 million, with selling and marketing expenses down 10.1% [6][8]. - Net income was $25.3 million, a decrease of 33.7% from the previous year, with diluted earnings per share at $0.26 compared to $0.38 [7][9]. Market Trends and Brand Performance - Total retail takeaway for Simply Good Foods increased by approximately 1.8%, driven by Quest and OWYN's growth of 12.0% and 17.8% respectively, while Atkins declined by 19.3% [4]. - The company is focused on long-term growth, particularly for Quest and OWYN, and plans to increase marketing spending to support these brands [13][14]. Outlook and Strategic Initiatives - The company expects stronger performance in the second half of the fiscal year, with anticipated margin expansion and Adjusted EBITDA growth beginning in the third quarter [15][16]. - The company has increased its share repurchase program by $200 million, with approximately $224 million available under the revised program as of January 6, 2026 [12][11]. Balance Sheet and Cash Flow - As of the end of the first quarter, the company had cash of $194.1 million and a term loan balance of $400.0 million, resulting in a Net Debt to Adjusted EBITDA ratio of 0.8x [10][47]. - Cash flow from operations was approximately $50.1 million, an increase from $32.0 million in the comparable year-ago period, primarily due to improved working capital [10][36].